company background image
SGT

Seagen DB:SGT Stock Report

Last Price

€127.36

Market Cap

€23.7b

7D

-1.4%

1Y

8.8%

Updated

05 Feb, 2023

Data

Company Financials +

SGT Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

SGT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$127.36
52 Week HighUS$184.02
52 Week LowUS$101.34
Beta0.57
1 Month Change-0.30%
3 Month Change0.094%
1 Year Change8.78%
3 Year Change20.15%
5 Year Change208.75%
Change since IPO4,048.53%

Recent News & Updates

Recent updates

Shareholder Returns

SGTDE BiotechsDE Market
7D-1.4%-4.4%2.7%
1Y8.8%6.0%-7.1%

Return vs Industry: SGT exceeded the German Biotechs industry which returned 6% over the past year.

Return vs Market: SGT exceeded the German Market which returned -7.1% over the past year.

Price Volatility

Is SGT's price volatile compared to industry and market?
SGT volatility
SGT Average Weekly Movement5.7%
Biotechs Industry Average Movement5.7%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: SGT is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SGT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,675David Epsteinhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGT fundamental statistics
Market Cap€23.73b
Earnings (TTM)-€589.84m
Revenue (TTM)€1.73b

13.7x

P/S Ratio

-40.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGT income statement (TTM)
RevenueUS$1.86b
Cost of RevenueUS$1.68b
Gross ProfitUS$184.76m
Other ExpensesUS$821.53m
Earnings-US$636.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 15, 2023

Earnings per share (EPS)-3.43
Gross Margin9.91%
Net Profit Margin-34.16%
Debt/Equity Ratio0%

How did SGT perform over the long term?

See historical performance and comparison